Shots:
- Appia Bio to receive $875M as an up front, equity investment, and milestone along with royalties. Kite will be responsible for the development, manufacturing, and commercialization of the product identified through the collaboration
- The collaboration will utilize Kite’s chimeric Ag receptors and Appia Bio’s allogeneic cell technology platform to develop off-the-shelf cell therapies
- Appia Bio will lead preclinical and early clinical research of two HSC-derived CAR-iNKT products with CARs provided by Kite
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer first appeared on PharmaShots.
